ClinicalTrials.gg
CompletedNCT00748111TIDEUpdated Feb 13, 2026

Thrombus and Inflammation Study in Sudden Cardiac DEath

An interventional study of Blood sample in Sudden Cardiac Death and Acute Myocardial Infarction, sponsored by Assistance Publique - Hôpitaux de Paris. Completed at 1 site in France. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-02-13.

Sponsored by Assistance Publique - Hôpitaux de Paris · Not applicable, Interventional, and Basic science

Phase
Not applicable
Study type
Interventional
Enrollment
380
Allocation
Non-randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

Sudden death is a natural death occurring within one hour after the onset of symptoms. It remains a major public health problem and accounts for 5 to 10 % of the annual total mortality ie about 300.000 in the United States. Despite community-based interventions, overall survival remains below 5%. Better understanding of the mechanisms causing sudden death could allow early identification of high risk subjects and implementation of specific prevention strategies. The cause of more than 90% of sudden deaths is cardiac with ventricular fibrillation or fast ventricular tachycardia complicating an underlying heart disease. Coronary heart disease and its consequences account for at least 80% of sudden cardiac deaths. Several risk factors associated with sudden death and not with myocardial infarction have been identified in population-based studies. However, the relationship between the occurrence of a coronary artery occlusion and the onset of arrhythmia is unclear. In particular, coronary artery occlusion can be rapidly followed by chest pain, which acts as a signal and allows identification of patients for emergency reperfusion. However, in some cases, the coronary artery occlusion is followed by a sudden onset of arrhythmia and sudden death. Recent data suggest that acute coronary occlusion is caused by plaque erosion or rupture and is followed by an intense local inflammation and rapid thrombus formation. Our hypothesis is that the speed of thrombus formation and coronary occlusion determines the clinical symptoms. Slow and progressive thrombus formation is likely to induce myocardial pre-conditioning thereby reducing the occurrence of ventricular arrhythmia. In contrast, rapid thrombus formation followed by acute coronary artery occlusion and ischemia is more likely to trigger fatal ventricular arrhythmia. During angioplasty procedures, coronary artery thrombus are aspirated, providing the opportunity for pathological studies. The aim of the TIDE study (Thrombus and Inflammation in Sudden Death) is therefore to compare the composition and age of thrombus collected at the site of coronary occlusion in patients with sudden death due to acute coronary artery occlusion and patients with an acute myocardial infarction without ventricular arrhythmia. The following hypothesis will be tested : fresh thrombus is more frequent in patients with sudden cardiac death versus patients with acute myocardial infarction without ventricular arrhythmia.

Read the detailed description

Sudden death is a natural death occurring within one hour after the onset of symptoms. It remains a major public health problem and accounts for 5 to 10 % of the annual total mortality ie about 40 000 deaths in France and 300.000 in the United States.(1) Despite community-based interventions, overall survival remains below 5%. (2) Better understanding of the mechanisms causing sudden death could allow early identification of high risk subjects and implementation of specific prevention strategies. (3)The cause of more than 90% of sudden deaths is cardiac with ventricular fibrillation or fast ventricular tachycardia complicating an underlying heart disease. (4) Coronary heart disease and its consequences account for at least 80% of sudden cardiac deaths and hypertrophic and dilated cardiomyopathies account for another 10 to 15% of cardiac causes.(4,5) Several risk factors associated with sudden death and not with myocardial infarction have been identified in population-based studies.(6-10) However, the relationship between the occurrence of a coronary artery occlusion and the onset of arrhythmia is unclear.The Framingham study reported that sudden death occurred without prior manifestations of coronary heart disease in more than 50% of men and 65% of women. (11) Data from 10 countries from WHO MONICA PROJECT show that sudden deaths are more frequent than non sudden coronary deaths until age 60. (figure). In a study on the value of immediate coronary angiography and angioplasty in survivors of SCD, a recent coronary artery occlusion was found in over 50% of patients and unstable coronary artery lesions in 20% (12). In two series based on autopsies, the rate of coronary artery lesions in non-survivors of SCD was over 80% (13-15). In a study based on autopsies of non-survivors of SCD, fresh thrombus was found in a majority of cases. (2)Furthermore, noninflammatory plaque erosion was found as an underlying cause to thrombus formation in 40% of cases (14). In this case, thrombus is formed on a denuded endothelial plaque surface and is in direct contact with activated smooth muscle cells. In 211 patients with non-complicated acute myocardial infarction caused by acute coronary occlusion, SASKIA et al studied the age of intracoronary thrombi, aspirated during angioplasty (16). In at least 50% of patients, thrombi were days or weeks old, thereby suggesting ischemic pre-conditioning in this sub-group of acute myocardial infarction patients with no ventricular arrhythmia. Maier et al studied intra-coronary concentrations of selected inflammatory biomarkers in 42 patients with acute myocardial infarction (17). High levels of interleukin 6 and serum amyloid A were found at the occlusion site; and these levels were even higher in patients with no previous clinical symptoms before the acute myocardial infarction. These data suggest that plaque erosion or rupture is followed by an intense local inflammation and rapid thrombus formation. Our hypothesis is that the speed of thrombus formation and coronary occlusion determines the clinical symptoms. Slow and progressive thrombus formation is likely to induce myocardial pre-conditioning thereby reducing the occurrence of ventricular arrhythmia. In contrast, rapid thrombus formation followed by acute coronary artery occlusion and ischemia is more likely to trigger fatal ventricular arrhythmia. We also believe that a precise determination of endothelial cell apoptosis, plaque erosion, and systemic and local inflammation could shed light on the pathogenic mechanisms prevailing in SCD due to acute coronary artery occlusion. Protection and thrombectomy devices were recently developed to avoid distal embolisation during angioplasty procedures in saphenous vein graphs or during angioplasty for acute myocardial infarction. These devices provide the unique opportunity to harvest blood and thrombi from the site of coronary occlusion. The aspirate can be used to study the speed and the intensity of local thrombus formation. The use of such techniques could be extended to patients with a SCD due to an acute coronary artery occlusion and the data compared to that of patients with an acute myocardial infarction without ventricular arrhythmia. Furthermore, markers of endothelial cell apoptosis, local and systemic inflammatory biomarkers in the culprit coronary artery and in the systemic blood could be studied in such patients and also during angioplasty procedures performed in patients with stable coronary lesions.(18-23) The aim of the TIDE study (Thrombus and Inflammation in Sudden Death) is therefore to compare the composition and age of thrombus collected at the site of coronary occlusion in patients with sudden death due to acute coronary artery occlusion and patients with an acute myocardial infarction without ventricular arrhythmia. The following hypothesis will be tested : fresh thrombus is more frequent in patients with sudden cardiac death versus patients with acute myocardial infarction without ventricular arrhythmia. Furthermore, coronary artery and systemic blood samples will be drawn in both groups and before coronary angioplasty procedures in patients with stable angina pectoris to determine the role of local and systemic inflammation and endothelial cell apoptosis in these settings.

02

Conditions studied

  • Sudden Cardiac Death
  • Acute Myocardial Infarction

Keywords

  • Sudden death
  • Out of hospital cardiac arrest
  • Acute myocardial infarction
  • Acute coronary syndrome
03

In context

Death, Sudden, Cardiac

363 studies on the registry are indexed under Death, Sudden, Cardiac; 84 are open to participants now.

This study's enrollment of 380 is above the median of 126 across 135 interventional studies indexed under Death, Sudden, Cardiac.

Browse Death, Sudden, Cardiac studies →

Lead sponsor

Assistance Publique - Hôpitaux de Paris is the lead sponsor of 3,592 studies on the registry; 1,033 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with sudden cardiac death without coronary artery occlusion
  • Patients with acute myocardial infarction due to coronary artery occlusion
  • Patients with stable angina treated with coronary angioplasty
  • Written
  • Social security

Exclusion criteria

Exclusion Criteria:

  • Pregnancy
  • Small arteries that preclude the use of aspiration devices
  • Sudden death without coronary lesions
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
380 participants (actual)

Study arms

  • Experimental
    1

    Sudden cardiac death hospitalized

    Other: Blood sample

  • Experimental
    2

    Acute myocardial infarction

    Other: Blood sample

  • Experimental
    3

    Angioplasty procedures programmed

    Other: Blood sample

  • Experimental
    4

    Sudden cardiac death hospitalized without coronary syndrome

    Other: Blood sample

Interventions

  • OtherBlood sample

    Blood sample and thrombus sample

06

What researchers measure

Primary outcomes

  1. Age of thrombus collected at the site of acute coronary occlusion.

    Time frame: one day

Secondary outcomes

  1. Local and systemic inflammation and endothelial cell apoptosis in patients with sudden death due to acute coronary occlusion, acute myocardial infarction and stable angina treated with coronary angioplasty.

    Time frame: one day

07

Study locations

1 site
  • Hopital Cochin
    Paris, 75014, France
08

References and documents

Publications

  • Empana JP, Boulanger CM, Tafflet M, Renard JM, Leroyer AS, Varenne O, Prugger C, Silvain J, Tedgui A, Cariou A, Montalescot G, Jouven X, Spaulding C. Microparticles and sudden cardiac death due to coronary occlusion. The TIDE (Thrombus and Inflammation in sudden DEath) study. Eur Heart J Acute Cardiovasc Care. 2015 Feb;4(1):28-36. doi: 10.1177/2048872614538404. Epub 2014 Jun 9. PubMed 24912925 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2008, a primary completion of Apr 2012 and a completion of Dec 2012. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 31, 2008
First posted
Sep 8, 2008
Start
Aug 2008
Primary completionActual
Apr 2012
CompletionActual
Dec 2012
Last update
Feb 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00748111
Collaborators
Institut National de la Santé Et de la Recherche Médicale, France, URC-CIC Paris Descartes Necker Cochin
Responsible party
Sponsor
First posted
Sep 8, 2008
Start date
Aug 2008
Primary completion
Apr 2012
Completion
Dec 2012
Last update
Feb 13, 2026

Study contacts

Xavier JOUVEN, MD
principal investigator · Institut National de la Santé Et de la Recherche Médicale, France

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion